Molecular and clinical characterization of Galectin‐9 in glioma through 1,027 samples

In recent years, research on glioma immunotherapy have grown rapidly. However, the autoimmune‐like side effects that are caused by blocking immunological checkpoints hinder their clinical application in gliomas currently. Galectin‐9, a ligand for T‐cell immunoglobulin mucin 3, has shed a new light o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Feng, Ming, Haolang, Wang, Yingshuai, Yang, Yihan, Yi, Li, Li, Tao, Ma, Haiwen, Tong, Luqing, Zhang, Liang, Liu, Peidong, Li, Jiabo, Lin, Yu, Yu, Shengping, Ren, Bingcheng, Yang, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028024/
https://www.ncbi.nlm.nih.gov/pubmed/31609000
http://dx.doi.org/10.1002/jcp.29309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028024/
https://www.ncbi.nlm.nih.gov/pubmed/31609000
http://dx.doi.org/10.1002/jcp.29309

Ejemplares similares